| 第一作者及年份 | 国家 | 治疗方式 | 样本量 | D-二聚体 临界值 | 年龄 | 随访时间 | 检测方法 | NOS 评分 |
| Chan Liu 2020 | China | Chemotherapy | 178 | 0.55 mg/L | NA | NA | NA | 7 |
| Florian Moik 2020 | Austria | Chemotherapy | 99 | NA | 61 (55~67) | 155 months | quantitative latex assay | 8 |
| Huiping Li 2019 | China | chemotherapy | 57 | 0.8 ng/mL | 61 (35~84) | 50 months | latex agglutination assay | 7 |
| Kimberly Blackwell 2004 | America | Chemotherapy | 104 | 133.2 ng/dL | 61 (23~85) | >25 | immunoassay | 8 |
| Liming Zhu 2014 | China | Chemotherapy | 74 | 1.9 ug/mL | 55.5 (31~74) | NA | immunoturbidimetry | 7 |
| Manabu Yamamoto 2012 | Japan | Chemotherapy | 42 | 5 ug/mL | 70 | 33.6 | immunosorbent | 8 |
| Tingting Hong 2017 | China | Surgery, chemotherapy or radiotherapy | 505 | 216 ug/L | 63 (27~93) | 62 months | immunoturbidimetric assays | 9 |
| Yasutomo Ojima 2021 | Japan | surgery, chemotherapy | 304 | 1.0 ug/ml | 70 (36~93) | 99.1 months | luminescence immunoassay | 7 |
| 薛丽英2014 | 中国 | 化疗 | 40 | 5 mg/L | 70 | 36 | 酶联免疫法 | 8 |
| 赵爽爽2016 | 中国 | 化疗 | 62 | 0.8 mg/L | 35~84 | 50 | 免疫比浊度法 | 9 |